| Objectives:(1)Observe the clinical symptom control of patients after acupoint application,and explore the effective maintenance time of acupoint application for allergic asthma;(2)Observe the improvement of the patient's PEFpred%level after treatment,combined with the patient's clinical symptom control level,to provide a basis for clarifying the specifie therapeutic effect maintenance time of point application.Methods:The study subjects were patients with chronic bronchial asthma who were treated with acupoint application in the outpatient department of the Acupuncture and Moxibustion Rehabilitation Department of Jiangsu Traditional Chinese Medicine Hospital from June to August 2018.70 allergic asthma patients were screened for allergens.Allergen test results were positive in 39 cases,which were in the allergic asthma group;and 31 cases with negative results were in the non-allergic asthma group.Follow up every 3 months to record the patient's recent incidence(1)Pay close attention to the number of acute attacks 3,6,9 months after the end of treatment and the same period of the year before treatment,the 3rd,6th,and 9th after treatment The day symptoms,night symptoms,and ACT scores at the same period of the month and the year before treatment,based on the incidence of allergic asthma patients after acupoint application treatment,assess the patient's clinical symptom control level after treatment,and then clarify acupoint application treatment for allergy Effective duration of asthma.(2)Record the peak expiratory flow of asthma patients before and at the 3rd,6th,and 9th months after the treatment of asthma patients,calculate the percentage of peak expiratory flow and the normal predicted value of patients(PEFpred%),and improve the application of points The impact of airway function in patients with allergic asthma is evaluated,combined with the patient's clinical symptom control level,to provide a basis for clarifying the specific efficacy maintenance time of acupoint application.Results:(1)A total of 64 patients completed the study,including 33 in the allergic asthma group and 31 in the non-allergic asthma group.(2)Baseline comparison:There was no statistically significant difference between the two groups in terms of gender,age,course of disease,PEFpred%and other general information(P>0.05).(3)Number of acute outbreaks:?The number of acute asthma attacks in 3 and 6 months after treatment in the two groups was different from the same period last year(P<0.05);9 months after treatment,there was no difference from the same period last year(P>0.05);? Compared with the non-allergic asthma group,the number of acute onsets in the allergic asthma group at 3,6,and 9 months after the end of treatment was statistically significant(P<0.05).(4)Daytime symptom score results:? The daytime symptom scores of the two groups of patients at 3,6,and 9 months after treatment were statistically analyzed,which were different from the same period last year(P<0.05);In the allergic asthma group,the day symptom scores at 6 and 9 months after the end of treatment were not statistically significant(P>0.05);the day symptom scores at 3 months after the end of treatment were statistically significant(P<0.05).(5)Nocturnal symptom scoring results:?After 3,6,and 9 months of treatment,the nocturnal symptom scores of the two groups were statistically analyzed,which were significantly different from the same period last year(P<0.01);There was no statistically significant difference in the nocturnal symptom scores in sexual asthma group at 3,6,and 9 months after the end of treatment(P>0.05).(6)ACT score results:?The ACT scores of the two groups of patients were statistically analyzed at 3 and 6 months after the end of treatment,and there was a difference compared with the same period last year(P<0.05);There was no statistically significant difference in ACT scores at the 3rd and 9th months after the treatment(P>0.05);ACT scores at the 6th month after the treatment were statistically significant(P<0.05).(7)PEFpred%test results:?PEFpred%of patients in the two groups were statistically reduced at 3 and 6 months after treatment,compared with that before treatment(P<0.05);9 months after treatment,there was no difference compared with the baseline period(P>0.05)? Compared with the non-allergic asthma group,the PEFpred%results of the allergic asthma group at 3,6,and 9 months after the end of treatment were not statistically significant(P>0.05)Conclusion:(1)Acupoint application can significantly improve the clinical symptom control of patients with allergic asthma,reduce the number of acute onset of allergic asthma,and relieve the symptoms of allergic asthma during the day and night.6 months.(2)Acupoint application has significantly improved PEFpred%in patients with allergic asthma,probably by improving the airway ventilation function of patients with allergic asthma and improving the patient's symptom control level,so as to achieve a certain duration of efficacy. |
PDF Full Text Request